IDEAS home Printed from https://ideas.repec.org/r/eee/respol/v36y2007i4p566-589.html

The myth of the biotech revolution: An assessment of technological, clinical and organisational change

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Gilding, Michael & Brennecke, Julia & Bunton, Vikki & Lusher, Dean & Molloy, Peter L. & Codoreanu, Alex, 2020. "Network failure: Biotechnology firms, clusters and collaborations far from the world superclusters," Research Policy, Elsevier, vol. 49(2).
  2. Andreas Reinstaller & Gerhard Schwarz, 2012. "Die wirtschafts- und forschungspolitische Bedeutung der Umsetzung der Biopatentrichtlinie im österreichischen Patentgesetz," WIFO Studies, WIFO, number 44635.
  3. Francesco Fallucchi & Jan Niederreiter & Massimo Riccaboni, 2021. "Learning and dropout in contests: an experimental approach," Theory and Decision, Springer, vol. 90(2), pages 245-278, March.
  4. Ali, Ayfer & Gittelman, Michelle, 2016. "Research paradigms and useful inventions in medicine: Patents and licensing by teams of clinical and basic scientists in Academic Medical Centers," Research Policy, Elsevier, vol. 45(8), pages 1499-1511.
  5. Valérie Sabatier & Vincent Mangematin & Tristan Rouselle, 2010. "From Business model to Business model portfolio in the european biopharmaceutical industry," Post-Print hal-00430782, HAL.
  6. Dosi, Giovanni & Nelson, Richard R., 2010. "Technical Change and Industrial Dynamics as Evolutionary Processes," Handbook of the Economics of Innovation, in: Bronwyn H. Hall & Nathan Rosenberg (ed.), Handbook of the Economics of Innovation, edition 1, volume 1, chapter 0, pages 51-127, Elsevier.
  7. Varshney, Mayank & Jain, Amit, 2023. "Technology acquisition following inventor exit in the biopharmaceutical industry," Technovation, Elsevier, vol. 126(C).
  8. Anckaert, Paul-Emmanuel & Cassiman, David & Cassiman, Bruno, 2020. "Fostering practice-oriented and use-inspired science in biomedical research," Research Policy, Elsevier, vol. 49(2).
  9. Angelo Kenneth S. Romasanta & Peter Sijde & Jacqueline Muijlwijk-Koezen, 2020. "Innovation in pharmaceutical R&D: mapping the research landscape," Scientometrics, Springer;Akadémiai Kiadó, vol. 125(3), pages 1801-1832, December.
  10. Stuart Hogarth & Paul Martin, 2021. "The ratio of vision to data: Promoting emergent science and technologies through promissory regulation, the case of the FDA and personalised medicine," Regulation & Governance, John Wiley & Sons, vol. 15(3), pages 969-986, July.
  11. Anckaert, Paul-Emmanuel, 2025. "When the drugs (don’t) work: The role of science in product commercialization," Research Policy, Elsevier, vol. 54(5).
  12. Irina Dezhina & V. Kiseleva, 2008. "State, Science and Business in Russia's Innovation System," Research Paper Series, Gaidar Institute for Economic Policy, issue 115P.
  13. Giovanni Dosi & Xiaodan Yu, 2018. "Capabilities Accumulation and Development: What History Tells the Theory," LEM Papers Series 2018/27, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
  14. Vargas-Peláez, Claudia Marcela & Soares, Luciano & Rover, Marina Raijche Mattozo & Blatt, Carine Raquel & Mantel-Teeuwisse, Aukje & Rossi Buenaventura, Francisco Augusto & Restrepo, Luis Guillermo & L, 2017. "Towards a theoretical model on medicines as a health need," Social Science & Medicine, Elsevier, vol. 178(C), pages 167-174.
  15. Joanna Chataway & Sarah Parks & Elta Smith, 2017. "How Will Open Science Impact on University-Industry Collaboration?," Foresight and STI Governance, National Research University Higher School of Economics, vol. 11(2), pages 44-53.
  16. Ribeiro, Barbara & Shapira, Philip, 2020. "Private and public values of innovation: A patent analysis of synthetic biology," Research Policy, Elsevier, vol. 49(1).
  17. K D S Fernald & H P G Pennings & J F van den Bosch & H R Commandeur & E Claassen, 2017. "The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-22, February.
  18. Roberta Piergiovanni & Enrico Santarelli, 2013. "The more you spend, the more you get? The effects of R&D and capital expenditures on the patenting activities of biotechnology firms," Scientometrics, Springer;Akadémiai Kiadó, vol. 94(2), pages 497-521, February.
  19. Kotiranta, Annu – Kulvik & Tahvanainen, Antti – Trieste, . "Raiders Of Lost Value," ETLA B, The Research Institute of the Finnish Economy, number 267.
  20. Kenneth Zahringer & Christos Kolympiris & Nicholas Kalaitzandonakes, 2018. "Time to patent at the USPTO: the case of emerging entrepreneurial firms," The Journal of Technology Transfer, Springer, vol. 43(4), pages 923-952, August.
  21. Aarden, Erik & Van Hoyweghen, Ine & Horstman, Klasien, 2011. "Constructing access in predictive medicine. Comparing classification for hereditary breast cancer risks in England, Germany and the Netherlands," Social Science & Medicine, Elsevier, vol. 72(4), pages 553-559, February.
  22. Alberto Onetti & Hal Steger, 2007. "Formulating an open source business model requires community segmentation and targeted marketing," Economics and Quantitative Methods qf0707, Department of Economics, University of Insubria.
  23. Tylecote, Andrew, 2019. "Biotechnology as a new techno-economic paradigm that will help drive the world economy and mitigate climate change," Research Policy, Elsevier, vol. 48(4), pages 858-868.
  24. Jing Zhang & Charles Baden‐Fuller, 2010. "The Influence of Technological Knowledge Base and Organizational Structure on Technology Collaboration," Journal of Management Studies, Wiley Blackwell, vol. 47(4), pages 679-704, June.
  25. Jorge Niosi & Maureen McKelvey, 2018. "Relating business model innovations and innovation cascades: the case of biotechnology," Journal of Evolutionary Economics, Springer, vol. 28(5), pages 1081-1109, December.
  26. Antonio Messeni Petruzzelli & Daniele Rotolo & Vito Albino, 2014. "Determinants of Patent Citations in Biotechnology: An Analysis of Patent Influence Across the Industrial and Organizational Boundaries," SPRU Working Paper Series 2014-05, SPRU - Science Policy Research Unit, University of Sussex Business School.
  27. DiVito, Lori, 2012. "Institutional entrepreneurship in constructing alternative paths: A comparison of biotech hybrids," Research Policy, Elsevier, vol. 41(5), pages 884-896.
  28. Bergek, Anna & Berggren, Christian & Magnusson, Thomas & Hobday, Michael, 2013. "Technological discontinuities and the challenge for incumbent firms: Destruction, disruption or creative accumulation?," Research Policy, Elsevier, vol. 42(6), pages 1210-1224.
  29. Billette de Villemeur, Etienne & Scannell, Jack & Versaevel, Bruno, 2021. "Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?," MPRA Paper 108233, University Library of Munich, Germany.
  30. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
  31. Wydra, Sven, 2009. "Production and employment impacts of new technologies: analysis for biotechnology," FZID Discussion Papers 08-2009, University of Hohenheim, Center for Research on Innovation and Services (FZID).
  32. Jing Liu & Mengbo Wang & Xiaoling Kang & Xia Zhang & Xing Chen, 2022. "Seizing the opportunity window of artificial intelligence in China: Towards an innovation policy mix framework for emerging technologies from an evolution perspective," Systems Research and Behavioral Science, Wiley Blackwell, vol. 39(3), pages 397-414, May.
  33. Andersson, Tord & Gleadle, Pauline & Haslam, Colin & Tsitsianis, Nick, 2010. "Bio-pharma: A financialized business model," CRITICAL PERSPECTIVES ON ACCOUNTING, Elsevier, vol. 21(7), pages 631-641.
  34. Gittelman, Michelle, 2016. "The revolution re-visited: Clinical and genetics research paradigms and the productivity paradox in drug discovery," Research Policy, Elsevier, vol. 45(8), pages 1570-1585.
  35. Ohid Yaqub, 2018. "Variation in the dynamics and performance of industrial innovation: what can we learn from vaccines and HIV vaccines?," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 27(1), pages 173-187.
  36. Nahuis, Roel & Stemerding, Dirk, 2013. "Genomics as a new research regime? Evidence from the Netherlands," Research Policy, Elsevier, vol. 42(3), pages 676-687.
  37. Alessia Pisoni & Alberto Onetti & Luciano Fratocchi & Marco Talaia, 2010. "Managing R&D activities in the Italian red biotech industry. A comparison between Italian independent firms and multinational companies," Economics and Quantitative Methods qf1003, Department of Economics, University of Insubria.
  38. Chen, Shih-Hsin & Lin, Wei-Ting, 2017. "The dynamic role of universities in developing an emerging sector: a case study of the biotechnology sector," Technological Forecasting and Social Change, Elsevier, vol. 123(C), pages 283-297.
  39. Lauto, Giancarlo & Valentin, Finn, 2016. "The knowledge production model of the New Sciences: The case of Translational Medicine," Technological Forecasting and Social Change, Elsevier, vol. 111(C), pages 12-21.
  40. Fabio Sorrentino & Francesco Garraffo, 2012. "Explaining performing R&D through alliances: Implications for the business model of Italian dedicated biotech firms," Journal of Management & Governance, Springer;Accademia Italiana di Economia Aziendale (AIDEA), vol. 16(3), pages 449-475, August.
  41. Medina-Molotla, Nelly & Thorsteinsdóttir, Halla & Frixione, Eugenio & Kuri-Harcuch, Walid, 2017. "Some factors limiting transfer of biotechnology research for health care at Cinvestav: A Mexican scientific center," Technology in Society, Elsevier, vol. 48(C), pages 1-10.
  42. Clemens Blümel, 2018. "Translational research in the science policy debate: a comparative analysis of documents," Science and Public Policy, Oxford University Press, vol. 45(1), pages 24-35.
  43. Andreas Reinstaller & Gerhard Schwarz, 2013. "Die Bedeutung und Nutzung von Biotechnologie-Patenten in Österreich," WIFO Monatsberichte (monthly reports), WIFO, vol. 86(3), pages 237-251, March.
  44. Nikulainen, Tuomo & Kulvik, Martti, 2009. "How General Are General Purpose Technologies? Evidence from nano-, bio- and ICT-technologies in Finland," Discussion Papers 1208, The Research Institute of the Finnish Economy.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.